Aureus Asset Management LLC Sells 313 Shares of Stryker Co. (NYSE:SYK)

Aureus Asset Management LLC cut its position in shares of Stryker Co. (NYSE:SYK) by 21.3% during the third quarter, HoldingsChannel.com reports. The firm owned 1,155 shares of the medical technology company’s stock after selling 313 shares during the period. Aureus Asset Management LLC’s holdings in Stryker were worth $417,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Kestra Investment Management LLC bought a new stake in shares of Stryker during the third quarter valued at approximately $346,000. B&L Asset Management LLC bought a new stake in shares of Stryker during the third quarter valued at approximately $279,000. Erste Asset Management GmbH bought a new stake in shares of Stryker during the third quarter valued at approximately $34,264,000. Edgestream Partners L.P. grew its position in Stryker by 216.1% in the third quarter. Edgestream Partners L.P. now owns 3,430 shares of the medical technology company’s stock valued at $1,239,000 after acquiring an additional 2,345 shares during the period. Finally, Ironwood Investment Counsel LLC grew its position in Stryker by 1.5% in the third quarter. Ironwood Investment Counsel LLC now owns 3,293 shares of the medical technology company’s stock valued at $1,190,000 after acquiring an additional 49 shares during the period. 77.09% of the stock is currently owned by institutional investors.

Insider Activity

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the transaction, the chief executive officer now owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. This represents a 36.43 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP M Kathryn Fink sold 2,121 shares of the stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $370.00, for a total value of $784,770.00. Following the completion of the transaction, the vice president now directly owns 10,042 shares in the company, valued at $3,715,540. The trade was a 17.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 66,781 shares of company stock valued at $24,612,275 over the last 90 days. 5.50% of the stock is owned by company insiders.

Stryker Trading Up 1.0 %

Shares of SYK opened at $392.15 on Monday. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66. Stryker Co. has a 12-month low of $285.79 and a 12-month high of $398.20. The firm has a market capitalization of $149.50 billion, a PE ratio of 42.03, a price-to-earnings-growth ratio of 2.96 and a beta of 0.94. The stock’s fifty day simple moving average is $368.51 and its 200-day simple moving average is $351.74.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The business had revenue of $5.49 billion for the quarter, compared to analyst estimates of $5.37 billion. During the same quarter in the prior year, the firm posted $2.46 earnings per share. The firm’s revenue for the quarter was up 11.9% compared to the same quarter last year. As a group, research analysts predict that Stryker Co. will post 12.06 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on SYK. BTIG Research upped their price target on Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Canaccord Genuity Group upped their price target on Stryker from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. UBS Group upped their price target on Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Wolfe Research began coverage on Stryker in a research report on Tuesday, September 10th. They issued an “outperform” rating and a $405.00 price target on the stock. Finally, Robert W. Baird upped their price target on Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $393.65.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.